VAX-24 Vaccine Proceeds in Infant Phase 2 Study for Preventing Invasive Pneumococcal Disease

Vaxcyte, Inc. today announced it has completed enrollment for its Infant Phase 2 clinical study evaluating VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) engineered to prevent invasive pneumococcal disease (IPD).

The primary three-dose immunization series is expected to produce topline safety, tolerability, and immunogenicity data by the end of the first quarter of 2025. And the booster dose results will be announced by the end of 2025.

These results will be crucial in demonstrating the effectiveness of VAX-24 and its potential to protect humankind from bacterial diseases.

"Despite the effectiveness of current vaccines, IPD, which includes meningitis and bacteremia, remains persistent in the first years of life and is a leading cause of invasive disease in children two years of age and under," said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte, in a press release on March 4, 2024.

Vaxcyte's carrier-sparing PCV franchise candidates include VAX-24 and VAX-31, the Company's next-generation 31-valent PCV currently being evaluated in a Phase 1/2 study, are being studied to prevent IPD.